Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis,Asia-Pacific Journal of Clinical Oncology

当前位置： X-MOL 学术 › Asia Pac. J. Clin. Oncol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis
Asia-Pacific Journal of Clinical Oncology ( IF 1.4 ) Pub Date : 2022-09-09 , DOI: 10.1111/ajco.13840
Daiki Takatsuka ₁ , Masataka Sawaki ₁ , Masaya Hattori ₁ , Akiyo Yoshimura ₁ , Haruru Kotani ₁ , Ayumi Kataoka ₁ , Nanae Horisawa ₁ , Yuri Ozaki ₁ , Yuka Endo ₁ , Kazuki Nozawa ₁ , Hiroji Iwata ₁

Affiliation

Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in combination with endocrine therapy (ET) have been approved for breast cancer (BC) treatment. Several trials suggested that arthralgia was reduced in patients treated with ET plus CDK4/6i compared with that in those with ET-alone. We aimed to compare arthralgia rates in BC patients treated with/without CDK4/6i. We reviewed randomized controlled phase II/III trials investigating CDK4/6i with ET in hormone receptor-positive and epidermal growth factor 2-negative BC. Publications were retrieved from PubMed from January 2014 to April 2021. We compared arthralgia rates between patients who were administered ET plus CDK4/6i (CDK4/6i group) and those treated with ET-alone (control group). We reviewed 12 trials that reported data on adverse effects for arthralgia. These trials included 17,440 patients (9255 in the CDK4/6i group and 8185 in the control group). The arthralgia rate in the CDK4/6i group was significantly lower than that in the control group (27.6% vs. 34.8%, p < .001), especially in early BC (28.8% vs. 37.3%, p < .001). These suggested that the arthralgia rate in patients treated with ET plus CDK4/6i was lower than that in patients treated with ET-alone and that CDK4/6i may decrease the arthralgia rate in BC patients treated with ET, especially in early BC.

中文翻译：

乳腺癌内分泌治疗联合或不联合细胞周期蛋白依赖性激酶 4/6 抑制剂引起的关节痛：系统评价和荟萃分析

细胞周期蛋白依赖性激酶 4/6 抑制剂 (CDK4/6i) 联合内分泌治疗 (ET) 已被批准用于乳腺癌 (BC) 治疗。多项试验表明，与单独接受 ET 治疗的患者相比，接受 ET 加 CDK4/6i 治疗的患者关节痛减轻。我们的目的是比较接受/不接受 CDK4/6i 治疗的 BC 患者的关节痛发生率。我们回顾了在激素受体阳性和表皮生长因子 2 阴性 BC 中研究 CDK4/6i 与 ET 的随机对照 II/III 期试验。从 PubMed 检索 2014 年 1 月至 2021 年 4 月的出版物。我们比较了接受 ET 加 CDK4/6i 治疗的患者（CDK4/6i 组）和仅接受 ET 治疗的患者（对照组）之间的关节痛发生率。我们回顾了 12 项报告关节痛不良反应数据的试验。这些试验包括 17,440 名患者（CDK4/6i 组 9255 名，对照组 8185 名）。CDK4/6i 组的关节痛发生率显着低于对照组（27.6% vs. 34.8%，p < .001），尤其是在 BC 早期（28.8% vs. 37.3%，p < .001）。这些表明，接受 ET 加 CDK4/6i 治疗的患者的关节痛发生率低于单独接受 ET 治疗的患者，并且 CDK4/6i 可能会降低接受 ET 治疗的 BC 患者的关节痛发生率，尤其是在早期 BC。

更新日期：2022-09-09

点击分享查看原文

点击收藏

阅读更多本刊最新论文本刊介绍/投稿指南11